Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide

Obesity represents a major contributor to cardiovascular disease burden, particularly in resource-limited settings where prevention, early detection, and long-term management remain challenging. Excess adiposity promotes cardiometabolic dysfunction through interconnected pathways involving insulin resistance, chronic low-grade inflammation, dyslipidemia, neurohormonal activation, and adverse cardiac remodeling, ultimately increasing the risk of heart failure, ischemic heart disease, stroke, and major adverse cardiovascular events. Among emerging therapeutic targets, incretin-based pathways have gained particular attention because they address both weight reduction and cardiovascular risk modification. Semaglutide, a glucagon-like peptide-1 receptor agonist, has become one of the most clinically relevant agents in this field, with evidence showing substantial reductions in body weight and improvements in glycemic control, visceral adiposity, systemic inflammation, blood pressure, and cardiometabolic risk markers. Data further support the potential role of semaglutide in reducing cardiovascular events, including among individuals with obesity and established cardiovascular disease without type 2 diabetes. The aim of the review is to synthesize current mechanistic and clinical evidence on semaglutide as an emerging therapeutic strategy in obesity management for cardiovascular risk reduction, while briefly contextualizing its role among other novel anti-obesity pharmacotherapies. Particular attention is also given to the relevance of semaglutide in resource-limited settings. Understanding organ-specific mechanisms and prioritizing scalable interventions may support more effective cardiovascular disease risk reduction strategies in obesity within resource-constrained healthcare systems.

Authors

Institutions

Publication Details

Journal
Narra X
Published
2026-11-16
DOI
https://doi.org/10.52225/narrax.v4i3.381
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide

Antonia Anna Lukito, Anwar Santoso, Erwinanto Erwinanto, Badai Bhatara Tiksnadi et al.
4 links
Narra X
Pharmacology and Obesity Treatment
article

Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide

Antonia Anna Lukito, Anwar Santoso, Erwinanto Erwinanto, Badai Bhatara Tiksnadi, Jordan Bakhriansyah, Habibie Arifianto, Yudi Her Octaviono, Ade M. Ambari, Haryadi Haryadi, Siska S. Danny
article en

Abstract

Obesity represents a major contributor to cardiovascular disease burden, particularly in resource-limited settings where prevention, early detection, and long-term management remain challenging. Excess adiposity promotes cardiometabolic dysfunction through interconnected pathways involving insulin resistance, chronic low-grade inflammation, dyslipidemia, neurohormonal activation, and adverse cardiac remodeling, ultimately increasing the risk of heart failure, ischemic heart disease, stroke, and major adverse cardiovascular events. Among emerging therapeutic targets, incretin-based pathways have gained particular attention because they address both weight reduction and cardiovascular risk modification. Semaglutide, a glucagon-like peptide-1 receptor agonist, has become one of the most clinically relevant agents in this field, with evidence showing substantial reductions in body weight and improvements in glycemic control, visceral adiposity, systemic inflammation, blood pressure, and cardiometabolic risk markers. Data further support the potential role of semaglutide in reducing cardiovascular events, including among individuals with obesity and established cardiovascular disease without type 2 diabetes. The aim of the review is to synthesize current mechanistic and clinical evidence on semaglutide as an emerging therapeutic strategy in obesity management for cardiovascular risk reduction, while briefly contextualizing its role among other novel anti-obesity pharmacotherapies. Particular attention is also given to the relevance of semaglutide in resource-limited settings. Understanding organ-specific mechanisms and prioritizing scalable interventions may support more effective cardiovascular disease risk reduction strategies in obesity within resource-constrained healthcare systems.

Narra XVol. 4(3)
Pelita Harapan University (ID), Sebelas Maret University (ID), University of Surabaya (ID), Universitas Airlangga (ID), University of Indonesia (ID), Dr. Hasan Sadikin General Hospital (ID), Universitas 45 Surabaya (ID), Padjadjaran University (ID)
Novo Nordisk
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon